Previous 10 | Next 10 |
2023-08-09 16:20:08 ET Harrow Health press release ( NASDAQ: HROW ): Q2 Non-GAAP EPS of -$0.02. Revenue of $33.5M (+43.8% Y/Y) beats by $2.46M . For further details see: Harrow Health Non-GAAP EPS of -$0.02, revenue of $33.5M beats by $2.46M
Second Quarter 2023 and Recent Selected Highlights: Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter. GAAP net loss of ($4.2) million. Record adjusted EBITDA of $11.0...
2023-08-01 11:00:00 ET Summary Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interesting given an 11.6% yield to maturity. ...
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bact...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also post its second quarter Letter to Stockholders t...
2023-07-19 12:17:07 ET Shares of Harrow Health (NASDAQ: HROW) were up more than 17% at 11 a.m. ET on Wednesday after the eye care pharmaceutical company made several big announcements after the market closed on Tuesday and before it opened on Wednesday. The stock is up more than...
2023-07-19 08:01:25 ET Harrow ( NASDAQ: HROW ) has priced an underwritten public offering of 3.38 million shares of its common stock at a price of $17.75/share for expected gross proceeds of $60 million. The stock is down 1.37% in premarket trade on Wednesd...
2023-07-19 07:38:43 ET Harrow Health ( NASDAQ: HROW ) has signed agreements with affiliates of Santen Pharmaceutical to acquire certain US and Canadian commercial rights for some of the branded ophthalmic products from the latter. The stock is down 0.5% in premar...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds of $60 million. The offering is expected to close on ...
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today an...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...